Clywedog Therapeutics is a small-molecule drug discovery company dedicated to developing first- and best-in-class therapies for the management and potential reversal of type 1 and type 2 diabetes.

We are at the forefront of metabolic health innovation, addressing critical unmet needs through innovative science and rigorous clinical evaluation.

Our programs focus on differentiated small molecules with unique selectivity and mechanisms of action designed to modulate immune responses and metabolic pathways that are pivotal to achieving disease-modifying outcomes in diabetes.

Clywedog was co-founded and seed-funded by Orbimed Advisors and Torrey Pines Investment, with additional support from the Expert Systems hybrid AI/ML drug discovery and development accelerator.